14 completed. 14 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 14 |
| Phase 2 | 1 | Completed 1 |
Follow relacorilant: new trials by email Literature Review of relacorilant trials Research Report on relacorilant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants Dabigatran Etexilate, Relacorilant - Cushing Syndrome, Neoplasms | Phase 1 | Completed | Corcept Therapeutics | 30 | 2022-05-25 | 2023-02-09 |
| T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers Relacorilant, Placebo to relacorilant, Moxifloxacin - Healthy | Phase 1 | Completed | Corcept Therapeutics | 36 | 2021-01-22 | 2021-09-14 |
| Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) Relacorilant, Pembrolizumab - Adrenocortical Carcinoma | Phase 1 | Completed | Corcept Therapeutics | 15 | 2020-09-30 | 2024-02-23 |
| A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects Relacorilant under fasted conditions, Relacorilant after a high-fat meal, Relacorilant after a low-fat meal - Healthy | Phase 1 | Completed | Corcept Therapeutics | 30 | 2020-09-19 | 2023-10-23 |
| A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant Relacorilant - Hepatic Impairment | Phase 1 | Completed | Corcept Therapeutics | 30 | 2020-01-06 | 2023-10-23 |
| Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer Enzalutamide, Relacorilant - Prostate Cancer | Phase 1 | Completed | University of Chicago | 42 | 2018-10-23 | 2026-03-31 |
| A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants Relacorilant (3x100 mg softgel capsules), Relacorilant (3x100 mg hard-shell capsules), Relacorilant (6x50mg hard-shell capsules) - Healthy | Phase 1 | Completed | Corcept Therapeutics | 30 | 2018-05-24 | 2018-09-07 |
| Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites Relacorilant 350mg, Itraconazole, Relacorilant 300mg - Healthy | Phase 1 | Completed | Corcept Therapeutics | 52 | 2018-04-10 | 2020-03-24 |
| Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride - Healthy | Phase 1 | Completed | Corcept Therapeutics | 27 | 2018-03-06 | 2018-05-17 |
| Relacorilant Food Effect Study in Healthy Subjects Relacorilant Fasted, Relacorilant with a high fat breakfast, Relacorilant with a moderate breakfast - Healthy, Food-drug Interaction | Phase 1 | Completed | Corcept Therapeutics | 30 | 2018-01-16 | 2018-05-17 |
| A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects CORT125134 150 mg, CORT125134 250 mg, CORT125134 dose to be determined - Healthy | Phase 1 | Completed | Corcept Therapeutics | 32 | 2017-05-18 | 2023-10-23 |
| Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors Relacorilant with nab-paclitaxel - Solid Tumors | Phase 1 / Phase 2 | Completed | Corcept Therapeutics | 85 | 2016-05-23 | 2022-12-06 |
| A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects CORT125134 - Healthy | Phase 1 | Completed | Corcept Therapeutics | 8 | 2016-04-07 | 2023-10-23 |
| CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) CORT125134, Matching Placebo of CORT125134, Mifepristone - Healthy | Phase 1 | Completed | Corcept Therapeutics | 130 | 2014-09-01 | 2019-08-09 |
Cushing Syndrome (2) · ACTH Syndrome, Ectopic (1) · Adrenal Cortex Neoplasms (1) · Adrenal Gland Diseases (1) · Adrenocortical Carcinoma (1) · Adrenocortical Hyperfunction (1) · Carcinoma, Ovarian Epithelial (1) · Diabetes Mellitus, Type 2 (1) · Endocrine System Diseases (1) · Glucose Intolerance (1) · Hyperglycemia (1) · Hypertension (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Pathologic Processes (1)
Corcept Therapeutics (13) · University of Chicago (1)
United States (13) · United Kingdom (1)
Joseph Custodio, PhD (3) · Joseph Custodio (2) · Kirsteen Donaldson, FFPM,DM,FRCP (2) · Ada Lee, MD (1) · Andreas G Moraitis, MD (1) · Andreas Moraitis (1) · Hazel Hunt (1) · Pui Leung (1) · Russell Szmulewitz, MD (1)
2014 (1), P50CA180995 (1)